New-onset diabetes after transplantation.
New-onset diabetes after transplantation (NODAT) is associated with significant morbidity and mortality. Given the availability of simple diagnostic methods and the known benefits of strict glycemic control, patients should be screened frequently after organ transplantation. The management of NODAT is multifaceted and aimed at both treatment and prevention of complications. Evaluation of patient risk for post-transplant diabetes mellitus and its complications is an important consideration in initial selection and subsequent modification of the immunosuppressive regimen.
Pavlakis
Martha
M
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. mpavlaki@bidmc.harvard.edu
D003920:Diabetes Mellitus / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged
D007166:Immunosuppressive Agents